SM
CORT icon

SG3 Management’s Corcept Therapeutics CORT Stock Holding History

SG3 Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,500
Closed -$30K – 1039
2021
Q4 		$30K Sell
1,500
-15,600
-91% -$316K ﹤0.01% 975
2021
Q3 		$337K Sell
17,100
-63,400
-79% -$1.33M 0.01% 684
2021
Q2 		$1.77M Buy
80,500
+46,672
+138% +$1.04M 0.06% 335
2021
Q1 		$805K Buy
+33,828
New +$903K 0.02% 656
2020
Q4 		– Sell
-10,000
Closed -$211K – 1037
2020
Q3 		$174K Buy
+10,000
New +$159K 0.01% 745

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SG3 Management's CORT Position: Q1 2022 in Review

SG3 Management sold out of Corcept Therapeutics (CORT) in Q1 2022, closing a stake of 1,500 shares — an estimated $30K sold.

SG3 Management first reported a position in CORT in Q3 2020 and held it in 5 quarters. The position peaked at $1.77M in Q2 2021. 228 funds tracked by Wall St. Rank hold CORT as of Q1 2022.

  • SG3 Management reported no remaining Corcept Therapeutics position as of Q1 2022 after selling out during the quarter.
  • SG3 Management sold 1,500 Corcept Therapeutics shares in Q1 2022, an estimated $30K.
  • SG3 Management first reported a position in Corcept Therapeutics in Q3 2020 and held it in 5 quarters.
  • SG3 Management's Corcept Therapeutics position peaked at $1.77M in Q2 2021.
  • 228 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.